On Page 10 please substitute the following paragraph for the paragraph of lines 17-21.

-- As the C_{3-10} cycloalkyl group, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.2.2]nonyl, bicyclo ~~bycyclo~~[3.3.1]nonyl, bicyclo[4.2.1]nonyl, bicyclo[4.3.1]decyl and the like can be mentioned. --

On Page 22 please substitute the following paragraph for the paragraph of lines 26-30.

-- (2) a C_{2-10} alkenylene group (e.g., -CH=CH-, $-CH_2$-CH=CH-, -CH=CH-CH_2-, -CH=CH-CH_2-CH_2-, -$C(CH_3)_2$-CH=CH-, $-CH_2$-CH=CH-CH_2-, -CH_2-CH_2-CH=CH-, -CH=CH-CH=CH-, -CH=CH-CH_2-CH_2-CH_2-); (3) a C_{2-10} alkynylene group (e.g., ~~-C≡C-, -CH_2-C≡C-, -CH_2-C≡C-CH_2-CH_2-~~ C≡C-, $-CH_2$-C≡C-, $-CH_2$-C≡C-CH_2-CH_2-) --

On Page 31 please substitute the following paragraph for the paragraph of lines 12-15.

-- (35) an aromatic heterocyclic (e.g., thienyl, furyl, pyridyl, oxazolyl, thiazolyl, tetrazolyl, ~~pyridyl,~~ quinolyl, indolyl)-C_{7-13} aralkyloxy-carbonyl group (e.g., tetrazolylbenzyloxycarbonyl) --

On Page 53 please substitute the following paragraph for the paragraph of lines 1-2.

-- ~~dextrin,~~ pullulan, light silicic anhydride, synthetic aluminum silicate, magnesium aluminate metasilicate and the like. --

On Page 67 please substitute the following paragraph for the paragraph of lines 12-23.

-- Examples of the diuretic include xanthine derivatives (e.g., sodium salicylate and theobromine, calcium salicylate and theobromine etc.), thiazide preparations (e.g., ethiazide, cyclopenthiazide, trichloromethiazide ~~trichloromethyazide~~, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, polythiazide, methyclothiazide etc.), antialdosterone preparations (e.g., spironolactone, triamterene etc.), carbonate dehydratase inhibitors (e.g., acetazolamide and the like), chlorobenzenesulfonamide preparations (e.g., chlortalidone, mefruside, indapamide etc.), azosemide, isosorbide, etacrynic acid, piretanide, bumetanide, furosemide and the like.
--

On Page 70 please substitute the following paragraph for the paragraph of lines 26-27.

-- When Xa is an ethoxycarbonyl group, then Q is preferably a divalent chain hydrocarbon group. --

On Page 121 please substitute the following paragraph for the paragraph of lines 12-15.

-- ^{1}H-NMR (DMSO-d_6) δ:1.02 (9H, s), 1.06 (3H, d, J = 7.0 Hz), 1.16 (3H, t, J = 7.1 Hz), 2.37 (3H, s), 2.58 (3H, s), 2.95 (2H, s), 3.88 (2H, s), 4.11 (2H, q, J = 7.0 Hz), 4.77 (1H, q, J = 7.1 Hz), 7.13-7.16 (1H, m), 7.23-7.32 (3H, m), 8.24 (3H, s). --

On Page 145 please substitute the following paragraph for the paragraph of lines 12-15.

-- ^{1}H-NMR (DMSO-d_6) δ:0.96 (3H, t, J = 7.4 Hz), 1.35 (9H, s), 1.64-1.76 (2H, m), 2.33 (3H, s), 2.44 (3H, s), 2.67-2.72 (2H, m), 3.87 (2H, d, J = 4.5 Hz), 6.99 (1H, s), 7.16-7.22 (4H, m), 12.92 (1H, s). --

On Page 412 please substitute the following paragraph for the paragraph of lines 1 - 14.

-- methyl 4-aminothiophene-3-carboxylate (184 mg, 1.17 mmol) and 0-(7-azabenzotriazol-1-yl)-1,1,3,3-~~tetramethyluromium~~ tetramethyluronium hexafluorophosphate (HATU, 1.0 g, 1.75 mmol) were dissolved in N,N-dimethylformamide (10 mL) and the mixture was stirred at room temperature for 24 hrs. The reaction mixture was poured into saturated brine, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium hydrogen carbonate and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography to give methyl 4-({[5-{[(tert-butoxycarbonyl)amino]methyl}-6-isobutyl-2-methyl-4-(4-methylphenyl)pyridin-3-yl]acetyl}amino)thiophene-3-carboxylate (440 mg, yield 66%) as a white powder. --